77 related articles for article (PubMed ID: 11086964)
1. A clinician's comments on the cyclophosphamide hematotoxicity biologically based risk assessment model.
Atkins HL
J Toxicol Environ Health A; 2000 Nov; 61(5-6):529-38. PubMed ID: 11086964
[No Abstract] [Full Text] [Related]
2. Comments on a biochemical model of cyclophosphamide hematotoxicity.
Portier CJ; Parham FM
J Toxicol Environ Health A; 2000 Nov; 61(5-6):525-8. PubMed ID: 11086963
[No Abstract] [Full Text] [Related]
3. Comments on the Cox model of cyclophosphamide hematotoxicity.
Krishnan K
J Toxicol Environ Health A; 2000 Nov; 61(5-6):511-4. PubMed ID: 11086960
[No Abstract] [Full Text] [Related]
4. A biomathematical model of cyclophosphamide hematotoxicity.
Cox LA
J Toxicol Environ Health A; 2000 Nov; 61(5-6):501-10. PubMed ID: 11086959
[No Abstract] [Full Text] [Related]
5. From cyclophosphamide hematotoxicity to modeling cancer.
Luebeck EG
J Toxicol Environ Health A; 2000 Nov; 61(5-6):515-20. PubMed ID: 11086961
[No Abstract] [Full Text] [Related]
6. Review of the Cox model.
Chen C
J Toxicol Environ Health A; 2000 Nov; 61(5-6):521-3. PubMed ID: 11086962
[No Abstract] [Full Text] [Related]
7. Biologically based risk assessment model for cyclophosphamide hematotoxicity in animal species: concluding comments.
Andersen ME; Krewski D
J Toxicol Environ Health A; 2000 Nov; 61(5-6):543-52. PubMed ID: 11086966
[No Abstract] [Full Text] [Related]
8. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
Bibawi S; Abi-Said D; Fayad L; Anderlini P; Ueno NT; Mehra R; Khouri I; Giralt S; Gajewski J; Donato M; Claxton D; Braunschweig I; van Besien K; Andreeff M; Andersson BS; Estey EH; Champlin R; Przepiorka D
Am J Hematol; 2001 Aug; 67(4):227-33. PubMed ID: 11443634
[TBL] [Abstract][Full Text] [Related]
9. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
[TBL] [Abstract][Full Text] [Related]
10. Cumulative chemotherapy increases mafosfamide toxicity for normal progenitor cells in AML patients: rationale for cryopreserving adapted-dose purged marrow early in first complete remission.
Martin H; Bruecher J; Claudé R; Hoelzer D
Bone Marrow Transplant; 1993 Nov; 12(5):495-9. PubMed ID: 8298560
[TBL] [Abstract][Full Text] [Related]
11. [The role of SC-1(+)- and Thy-1(+)-cells in the regulation of cytokine production by cells of the bone marrow regenerating after cytostatic action].
Dygaĭ AM; Sherstoboev EIu; Gol'dberg ED
Biull Eksp Biol Med; 1998 Apr; 125(4):374-7. PubMed ID: 9631712
[No Abstract] [Full Text] [Related]
12. A novel anti-inflammatory function of human galectin-1: inhibition of hematopoietic progenitor cell mobilization.
Kiss J; Kunstár A; Fajka-Boja R; Dudics V; Tóvári J; Légrádi A; Monostori E; Uher F
Exp Hematol; 2007 Feb; 35(2):305-13. PubMed ID: 17258079
[TBL] [Abstract][Full Text] [Related]
13. Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia?
Vellenga E; van Putten WL; Boogaerts MA; Daenen SM; Verhoef GE; Hagenbeek A; Jonkhoff AR; Huijgens PC; Verdonck LF; van der Lelie J; Schouten HC; Gmür J; Wijermans P; Gratwohl A; Hess U; Fey MF; Löwenberg B
Bone Marrow Transplant; 1999 Jun; 23(12):1279-82. PubMed ID: 10414916
[TBL] [Abstract][Full Text] [Related]
14. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
15. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
[TBL] [Abstract][Full Text] [Related]
16. Activated lymphocytes in the marrow cell suspension decrease the mafosfamide-induced CFU-GM cytotoxicity.
Woźny T; Sawiński K; Kozłowska-Skrzypczak M; Hansz J
Acta Haematol Pol; 1995; 26(4):367-75. PubMed ID: 8571738
[TBL] [Abstract][Full Text] [Related]
17. In vitro sensitivity of human hematopoietic progenitor cells to 4-hydroperoxycyclophosphamide.
Ratajczak MZ; Ratajczak J; Kuczynski W; Light B; Lusk EJ; Gewirtz AM
Exp Hematol; 1993 Dec; 21(13):1663-7. PubMed ID: 8243568
[TBL] [Abstract][Full Text] [Related]
18. Review of the Cox hematotoxicity model.
Heaney ML; Nimer SD
J Toxicol Environ Health A; 2000 Nov; 61(5-6):539-41. PubMed ID: 11086965
[No Abstract] [Full Text] [Related]
19. [Therapy-related acute leukaemia and myelodysplastic syndrome].
Díaz Beveridge R; Aparicio Urtasun J
An Med Interna; 2003 May; 20(5):257-68. PubMed ID: 12831302
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo manipulation of hematopoietic stem cells for transplantation: the potential role of amifostine.
Balzarotti M; Grisanti S; Granzow K; Saladini A; Sala A; Nozza A; Molteni A; Passamonti F; Carlo-Stella C; Santoro A; Siena S
Semin Oncol; 1999 Apr; 26(2 Suppl 7):66-71. PubMed ID: 10348263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
